California’s Division of Workers’ Compensation (DWC) issued an update to the Physician and Non-Physician Practitioner portion of the Official Medical Fee Schedule (OMFS) for workers’ compensation, effective for all dates of service on or after October 1, 2022.
The update adds 31 new procedure codes, all reimbursable “By Report.” The update also alters the status of one existing procedure code, without affecting the reimbursement amount.
Read on for details.
The update conforms the OMFS to relevant 2022 fourth quarter changes to the Centers for Medicare and Medicaid Services (CMS) payment system, as required by California Labor Code Section 5307.1. The DWC announced the update in a recent Newsline, and posted the order adopting the update on the DWC website.
Listed below are the new Healthcare Common Procedure Coding System (HCPCS) codes adopted by the DWC (and CMS) beginning October 2022. All 31 of the new procedure codes are billable By Report (BR).
California Code of Regulations Section 9789.12.4 offers guidelines to determine appropriate reimbursement amounts for BR codes; essentially, providers find a comparable procedure in terms of time, skill, and resources required, and charge accordingly. The provider must justify the amount charged with a separate (non-reimbursable) report.
HCPCS |
Description |
Reimbursement |
A9602 |
Fluorodopa f-18 diag per mci |
By Report |
A9607 |
Lutetium lu 177 vipivotide |
By Report |
A9800 |
Gallium locametz 1 millicuri |
By Report |
G0310 |
Immunize counsel 5-15 min |
By Report |
G0311 |
Immunize counsel 16-30 mins |
By Report |
G0312 |
Immunize couns < 21yr 5-15 m |
By Report |
G0313 |
Immunize couns < 21yr 6-30 m |
By Report |
G0314 |
Counsel immune <21 16-30 m |
By Report |
G0315 |
Counsel immune <21á 5-15 m |
By Report |
J1302 |
Inj, sutimlimab-jome, 10 mg |
By Report |
J1932 |
Inj, lanreotide, (cipla) 1mg |
By Report |
J2777 |
Inj, faricimab-svoa, 0.1mg |
By Report |
J9274 |
Inj, tebentafusp-tebn, 1 mcg |
By Report |
J9298 |
Inj nivol relatlimab 3mg/1mg |
By Report |
Q2056 |
Ciltacabtagene car-pos t |
By Report |
Q5125 |
Inj, releuko 1 mcg |
By Report |
0041A |
Adm sarscov2 5mcg/0.5ml 1st |
By Report |
0042A |
Adm sarscov2 5mcg/0.5ml 2nd |
By Report |
0074A |
Adm sarscv2 10mcg trs-sucr b |
By Report |
0081A |
Adm sarscv2 3mcg trs-sucr 1 |
By Report |
0082A |
Adm sarscv2 3mcg trs-sucr 2 |
By Report |
0083A |
Adm sarscv2 3mcg trs-sucr 3 |
By Report |
0091A |
Adm sarscov2 50 mcg/.5 ml1st |
By Report |
0092A |
Adm sarscov2 50 mcg/.5 ml2nd |
By Report |
0093A |
Adm sarscov2 50 mcg/.5 ml3rd |
By Report |
0111A |
Adm sarscov2 25mcg/0.25ml1st |
By Report |
0112A |
Adm sarscov2 25mcg/0.25ml2nd |
By Report |
0113A |
Adm sarscov2 25mcg/0.25ml3rd |
By Report |
91304 |
Sarscov2 vac 5mcg/0.5ml im |
By Report |
91308 |
Sarscov2 vac 3 mcg trs-sucr |
By Report |
91311 |
Sarscov2 vac 25mcg/0.25ml im |
By Report |
In addition to the above additions, the DWC update alters the Status Codes of one existing procedure code; however, this code remains billable By Report.
HCPCS |
Description |
Change |
G9678 |
Oncology care model service |
Status Code change only. Remains "By Report." |
Lastly, providers may note that the 2022 Q4 update does not include a new telehealth procedure code list.
DaisyBill provides content as an insightful service to its readers and clients. It does not offer legal advice and cannot guarantee the accuracy or suitability of its content for a particular purpose.